Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 157,714 shares at $42.85 ($6.7M) on 2024-05-08, disclosed to the SEC on 2024-05-09.
Scheduled sale ($6.7M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.15 | 56,335 | $2.4M | 35.6% |
| 2 | $42.15 | 56,335 | $2.4M | 35.6% |
| 3 | $42.85 | 22,472 | $963K | 14.4% |
| 4 | $42.85 | 22,472 | $963K | 14.4% |
| 5 | $44.03 | 100 | $4K | 0.1% |
| Total | $42.35 avg | 157,714 |
| $6.7M |
| 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |